Literature DB >> 29405120

Pleomorphic Multinucleated Plasma Cells Simulating Megakaryocytes in an Anaplastic Variant of Myeloma.

Shivangi Harankhedkar1, Ruchi Gupta1, Khaliqur Rahman1.   

Abstract

Entities:  

Keywords:  Anaplastic Megakaryocytes.; Myeloma

Mesh:

Year:  2018        PMID: 29405120      PMCID: PMC5972346          DOI: 10.4274/tjh.2017.0329

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


× No keyword cloud information.
To the Editor, Myeloma cells are notorious for their morphological variations, which range from mature-appearing plasma cells to other poorly differentiated forms. The pleomorphic or anaplastic variants are its uncommon rare variants, which may pose a diagnostic dilemma in unprecedented cases. These anaplastic variants may mimic high-grade lymphomas, leukemia, or even metastatic carcinomas [1,2]. Anaplastic plasma cells may be seen at diagnosis or evolve during the terminal phase of the disease [3]. The correlation of this morphological variant with treatment outcome is controversial, but it is believed to be a harbinger of aggressive disease [4,5]. Herein we report the case of an unsuspected multiple myeloma, where bone marrow examination revealed the presence of bizarre plasma cells simulating megakaryocytes. An asymptomatic 65-year-old diabetic male presented with bicytopenia. Complete blood count analysis showed hemoglobin of 7 g/dL, total leukocyte count of 6.3x109/L, and 51x109/L platelets. The peripheral smear showed the presence of occasional circulating plasma cells with minimal rouleaux formation. Bone marrow examination revealed proliferation of highly pleomorphic cells with multinucleation, simulating megakaryocytes. Cells had moderate to abundant basophilic cytoplasm, while nuclei were multilobulated, with open chromatin and prominent nucleoli, along with a few intranuclear basophilic inclusions (Figure 1A). Serum protein electrophoresis revealed monoclonal protein of 0.19 g/dL, which was confirmed to be IgA kappa on immunofixation (Figure 1B). The kappa/lambda ratio was 427.6 and the β2 microglobulin level was 21.9 mg/L. Immunophenotypically, the cells expressed CD38, CD138, CD56, and CD200 (Figure 1C-1E). FISH analysis, performed after magnetic bead enrichment of plasma cells, showed the presence of del(13q14.3). The patient was unfortunately lost to follow-up.
Figure 1

Panel of photomicrographs: A) May-Grünwald Giemsa stained bone marrow aspirate smear (100x) showing pleomorphic cells, with multilobation and multinuclearity, with prominent inclusions (red arrows) and abundant basophilic cytoplasm, and absence of perinuclear hof; B) serum immunofixation highlighting presence of IgA kappa monoclonal protein; C, D, E) panel of dot plots documenting these atypical plasma cells to be positive for CD38, CD138, CD200, and CD56 and negative for CD45.

Anaplastic multiple myeloma (AMM) is a rare morphological variant of multiple myeloma, the true incidence of which is largely unknown [1,2,6,7]. In the early 1990s, Allen and Coleman [3] reviewed 108 cases of anaplastic myeloma, 68 of which showed the presence of extramedullary disease. Other salient characteristics of AMM, which have been observed by other authors, too, include a younger age atpresentation, cytopenias, predilection for IgA myelomas, and aggressive clinical course [4,7,8,9]. Bahmanyar et al. [10] reviewed the genetic features of 11 cases of AMM for the presence of myeloma-associated genetic abnormalities and compared them with 188 newly diagnosed non-anaplastic variants of MM. They observed significantly higher frequencies of 1q21 amplification, 17p(p53) deletion, and t(4, 14). Additionally, the presence of complex karyotype, del(13q14.3), t(1;19), and near tetraploidy has also been reported [8,9,10]. The treatment outcome of this variant is considered poor as per the older literature; however, patients treated with triple-drug chemotherapeutic regimens in the modern era have shown sustained responses [1,5,9]. To conclude, awareness of these variants in myeloma is important for an accurate diagnosis. In cases where myeloma cells show extreme “de-differentiation”, a multidisciplinary approach with the addition of immunophenotyping in the diagnostic armamentarium is recommended. With the advent of triple-drug regimens in myeloma therapy and autologous bone marrow transplantation, the outcome of this variant needs to be re-addressed inlarger studies.
  10 in total

1.  Anaplastic variant of plasma cell myeloma with Dutcher bodies.

Authors:  Hong Chang; Babita Kajal
Journal:  Blood       Date:  2016-06-23       Impact factor: 22.113

2.  Plasma cell myeloma with anaplastic transformation.

Authors:  Shenon Sethi; Ira Miller
Journal:  Blood       Date:  2016-10-20       Impact factor: 22.113

3.  Anaplastic myeloma: a morphologic diagnostic dilemma.

Authors:  Seema Rao; Rakhee Kar; Hara Prasad Pati
Journal:  Indian J Hematol Blood Transfus       Date:  2009-01-11       Impact factor: 0.900

4.  Anaplastic Variant of Plasma Cell Myeloma: A Pitfall of Morphlogical Identification.

Authors:  Renata Beljan Perak; Ivana Karaman; Dinka Sundov; Jasminka Jakelic Pitesa; Anela Novak; Antonia Pavlovic
Journal:  Acta Cytol       Date:  2016-07-19       Impact factor: 2.319

Review 5.  Aggressive phase multiple myeloma: a terminal anaplastic transformation resembling high-grade lymphoma.

Authors:  S L Allen; M Coleman
Journal:  Cancer Invest       Date:  1990       Impact factor: 2.176

6.  Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma.

Authors:  Mridul Agrawal; Jennifer Kanakry; Christina A Arnold; Daniel L Suzman; Luckson Mathieu; Yvette L Kasamon; Douglas E Gladstone; Richard F Ambinder; Nilanjan Ghosh
Journal:  Ann Hematol       Date:  2014-07       Impact factor: 3.673

7.  Aggressive plasma cell myeloma. A terminal phase.

Authors:  A L Suchman; M Coleman; J A Mouradian; D J Wolf; S Saletan
Journal:  Arch Intern Med       Date:  1981-09

8.  Genomic aberrations in anaplastic multiple myeloma: high frequency of 1q21(CKS1B) amplifications.

Authors:  Mohammad Bahmanyar; Xiaoying Qi; Hong Chang
Journal:  Leuk Res       Date:  2013-10-08       Impact factor: 3.156

9.  Anaplastic myeloma in systemic lupus erythematosus.

Authors:  R C Butler; S M Thomas; J M Thompson; A C Keat
Journal:  Ann Rheum Dis       Date:  1984-08       Impact factor: 19.103

10.  Anaplastic myeloma.

Authors:  K Zervas; N Constantinou; M Karakantza; V Tsigalidou-Balla
Journal:  Leuk Lymphoma       Date:  1995-02
  10 in total
  3 in total

1.  Anaplastic plasma cell myeloma - A morphological dilemma.

Authors:  Thulasi Raman Ramalingam; Lakshman Vaidhyanathan; Prabu Pandurangan
Journal:  Hematol Transfus Cell Ther       Date:  2020-08-05

2.  Anaplastic Multiple Myeloma: Case Series and Literature Review.

Authors:  Jian Wu; Emily Chu; Cristiana Costa Chase; Taewoong Choi; Cristina Gasparetto; Ken Young; Yubin Kang
Journal:  Asploro J Biomed Clin Case Rep       Date:  2022-01-15

3.  Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.

Authors:  Masuho Saburi; Masao Ogata; Yasuhiro Soga; Yoshiyuki Kondo; Ryo Kurimoto; Kazuhito Itani; Kazuhiro Kohno; Hiroki Uchida; Toshiyuki Nakayama
Journal:  J Clin Exp Hematop       Date:  2020
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.